<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9187843</article-id><article-id pub-id-type="pmcid-ver">PMC9187843.1</article-id><article-id pub-id-type="pmcaid">9187843</article-id><article-id pub-id-type="pmcaiid">9187843</article-id><article-id pub-id-type="pmid">35706739</article-id><article-id pub-id-type="doi">10.7759/cureus.24927</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Public Health</subject></subj-group><subj-group><subject>Dentistry</subject></subj-group></article-categories><title-group><article-title>COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Panneer Selvam</surname><given-names initials="S">Suganya</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramani</surname><given-names initials="P">Pratibha</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>R</surname><given-names initials="R">Ramya</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sundar</surname><given-names initials="S">Sandhya</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>T A</surname><given-names initials="L">Lakshmi</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Oral Pathology, Saveetha Dental College &amp; Hospital, Chennai, IND </aff><aff id="aff-2">
<label>2</label>
Oral Biology, Saveetha Dental College &amp; Hospital, Chennai, IND </aff><author-notes><corresp id="cor1">
Suganya Panneer Selvam <email>drsugan29@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>11</day><month>5</month><year>2022</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>5</month><year>2022</year></pub-date><volume>14</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">406626</issue-id><elocation-id>e24927</elocation-id><history><date date-type="accepted"><day>11</day><month>5</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>05</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>14</day><month>06</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 20:25:15.520"><day>28</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022, Panneer Selvam et al.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Panneer Selvam et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/3.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cureus-0014-00000024927.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cureus.com/articles/94423-covid-19-vaccines-and-the-efficacy-of-currently-available-vaccines-against-covid-19-variants">This article is available from https://www.cureus.com/articles/94423-covid-19-vaccines-and-the-efficacy-of-currently-available-vaccines-against-covid-19-variants</self-uri><abstract><p>Severe acute respiratory syndrome coronavirus 2 is the seventh member of the Coronaviridiae family of viruses, which are thought to be transmitted by Chinese horseshoe bats. The virus undergoes mutations leading to variants such as B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617 (delta), as well as the recent variant B.1.1.529 (omicron), which has around 30 deletions, making it a severely mutated form that lowers vaccination-induced protection. Vaccine efficacy is usually expressed as relative risk reduction, which is based on the ratio of attack rates with and without a vaccine, whereas absolute risk reduction is based on the entire population. Rather than two doses, recent research suggests that a third dose/booster dose may aid in protection against future variants. The constant influx of mutant variations is putting a strain on vaccine production. Despite the challenges, we are optimistic that the epidemic will be eradicated by achieving mass immunity and by ensuring that everyone receives vaccines at a faster rate.</p></abstract><kwd-group kwd-group-type="author"><kwd>covaxin</kwd><kwd>booster dose</kwd><kwd>efficacy</kwd><kwd>moderna</kwd><kwd>vaccine</kwd><kwd>omicron</kwd><kwd>corona</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="disclaimer">The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.</p></notes></front><body><sec sec-type="intro"><title>Introduction and background</title><p>Coronaviruses belong to the Coronaviridiae family in the Nidovirales order. Bats were considered to be the only reservoir, and the first animal to be documented was the Chinese horseshoe bats [<xref rid="REF1" ref-type="bibr">1</xref>-<xref rid="REF3" ref-type="bibr">3</xref>]. The human-to-human transmission of the virus occurs due to close contact with infected persons, and aerosols generated during coughing or sneezing can penetrate the human body during inhalation through the nose or mouth [<xref rid="REF4" ref-type="bibr">4</xref>]. The earliest case was documented in December 2019, and it is the seventh member of the coronavirus family to infect humans [<xref rid="REF5" ref-type="bibr">5</xref>]. The International Committee on Taxonomy of Viruses (ICTV) named the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease coronavirus disease 2019 (COVID-19). The higher transmission rate of SARS-CoV-2 could be a genetic recombination event at the S protein in the RBD region [<xref rid="REF4" ref-type="bibr">4</xref>]. The virus undergoes mutations resulting in variants such as B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617 (delta), and the newer variant omicron (B.1.1.529). Omicron has more than 30 deletions and is considered to be a heavily mutant variant that reduces vaccine-mediated immunity [<xref rid="REF6" ref-type="bibr">6</xref>]. Vaccines are the only tool to control this pandemic outbreak as no specific therapies have been introduced to date. Numerous vaccines have been manufactured, and this article provides information about COVID-19 vaccines and their efficacy against coronavirus variants.</p></sec><sec sec-type="review"><title>Review</title><p>Structure of COVID-19</p><p>Coronavirus is an enveloped virus approximately 120 nm in diameter with a single-stranded RNA genome. The RNA genome consists of a 5&#8217; methyl-guanosine cap, poly (A) tail, and 29,903 nucleotides. It consists of an open reading frame (ORF) encoding non-structural proteins for replication, four structural proteins (spike, envelope, membrane, nucleocapsid), and numerous accessory proteins. The spike glycoprotein binds to angiotensin-converting enzyme 2 (ACE2) in humans for cell entry. The spike protein is cleaved by host proteases into S1 and S2 subunits where S1 is responsible for receptor recognition and S2 for membrane fusion. S1 can be divided into the C-terminal domain and N-terminal domain, with the C-terminal domain showing a stronger affinity for human ACE2. After attachment, the conformational change in the S protein facilitates the fusion of the virus envelope with the cell membrane. The viral RNA genome is released into the cytoplasm and translated into viral replicase polyproteins pp1a and pp1ab3 which are cleaved into small products by virus-encoded proteinases. The polymerase transcribes a series of subgenomic mRNAs by discontinuous transcription which are finally translated into viral structural proteins (S, E, M, N proteins). The N protein combines with the positive-stranded genomic RNA to form a nucleoprotein complex. The structural protein and nucleoprotein complex are assembled within the viral envelope and then released from the infected cell [<xref rid="REF5" ref-type="bibr">5</xref>].</p><p>Entry mechanism of coronavirus</p><p>The glycoprotein spikes on the outer surface of the virus are responsible for the attachment and entry of the virus into host cells. The receptor-binding domain (RBD) is loosely attached among viruses and this is how it infects multiple hosts. Coronavirus depends on cellular proteases such as human airway trypsin-like protease (HAT), cathepsins, and transmembrane protease serine 2 that split the spike protein and help in further penetration. Research on animal studies has revealed that mutation at&#160;spike glycoprotein is responsible for severe infection and that therapeutic agents must target spike glycoproteins</p><p>COVID-19 vaccines</p><p>Broad-spectrum antibiotics and antiviral drugs were initially used; however, remdesivir has shown promising results. The blood plasma from recovered patients has been injected into infected patients and has shown rapid recovery. Monoclonal antibodies (CR3022) had been found to bind with the spike RBD of SARS-CoV-2 without overlapping with the ACE2 receptor-binding motif. The major hurdle in creating a vaccine is to overcome cross-resistance. Many companies such as Moderna Therapeutics, Inovio Pharmaceuticals, Novavax, Vir Biotechnology, Ster Mirna Therapeutics, Johnson &amp; Johnson, VIDO-Intervac, GeoVax-BravoVax, Clover Biopharmaceuticals, Curevac, and Codagenix had been working for the development of vaccines against COVID-19 [<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>RNA/DNA Vaccines</p><p>It uses the host cell&#8217;s transcription and translation processes to express the vaccine antigen that is encoded by the injected nucleotide. COVID-19 RNA-based vaccines are delivered in lipids, and the production is a very quick process [<xref rid="REF7" ref-type="bibr">7</xref>]. However, freezing huge amounts of the vaccine is challenging [<xref rid="REF8" ref-type="bibr">8</xref>]. The mRNA-1273 vaccine administered in lipid particles that encode for spike protein triggered a good antibody response [<xref rid="REF9" ref-type="bibr">9</xref>].</p><p>Viral Vector-Based Vaccines</p><p>The genetic sequence of the foreign viral antigen inserted into the genome is the baseline of viral vector vaccines. This antigen is either secreted inducing B-cell/antibody response or digested within the target cells inducing a potent CD8+T cell response [<xref rid="REF10" ref-type="bibr">10</xref>]. However, the vaccine could be neutralized if the vaccinated individuals have pre-existing antibodies against the vector virus. The recent viral vector vaccine against COVID-19 is mostly adenovirus-based. Antibody and T-cell responses were increased on day 28 after vaccination even after its reduction with the presence of pre-existing anti-adenovirus antibodies [<xref rid="REF11" ref-type="bibr">11</xref>]. ChAdOx1, also known as AZD1222 (Covishield), has increased antibody titers after a booster dose at 28 days [<xref rid="REF12" ref-type="bibr">12</xref>].</p><p>Protein-Based Vaccines</p><p>Protein-based vaccines/inactivated vaccines with aluminum salt adjuvants are currently used in routine childhood immunization. One such vaccine for COVID-19 is PiCoVacc, also called CoronaVac, for which clinical trials are ongoing in healthy individuals and the elderly population [<xref rid="REF13" ref-type="bibr">13</xref>,<xref rid="REF14" ref-type="bibr">14</xref>]. &#946;-propiolactone inactivated SARS-CoV-2WIV04 is another alum-adjuvanted strain with more antibody titers, but these types of vaccines have a chance of eliciting antibody enhancement of disease [<xref rid="REF15" ref-type="bibr">15</xref>,<xref rid="REF16" ref-type="bibr">16</xref>]. The other adjuvant vaccines in the trial are the adjuvanted S-trimer vaccine (SCB-19) and subunit vaccine NVX-CoV2373 adjuvanted with matrix-M1 saponins [<xref rid="REF17" ref-type="bibr">17</xref>].</p><p>Vaccines Based on Accentuated SARS-CoV-2 Viruses</p><p>This is the most traditional technique where the virus has been weakened so that it will not cause the disease. Though it is effective in strengthening the immune system and inducing a strong immune memory, none of the vaccines for COVID-19 have reached the stage of clinical trials [<xref rid="REF18" ref-type="bibr">18</xref>].</p><p>Vaccines Based on Inactivated SARS-CoV-2 Viruses</p><p>This vaccine is based on killed viruses but has a short immune memory. This is not only designed to direct against the spike protein but also many other SARS-CoV-2 antigens. CoronaVac and Sinopharm from China and Covaxin from India were successfully administered to the population after completing phase III trials [<xref rid="REF18" ref-type="bibr">18</xref>].</p><p>Vaccines Based on SARS-CoV-2 Proteins</p><p>The vaccines are based on the proteins present on the surface of microbes that are produced in vitro with the help of DNA recombinant technology. The targets of these vaccines are the spike protein and, to some extent, nucleoprotein. Novavax from the United States and Co-VLP have completed phase III trials and have been administered to the population in two doses [<xref rid="REF18" ref-type="bibr">18</xref>].</p><p>Naked DNA-Based Vaccines</p><p>DNA plasmids enter human cells after vaccination and induce cells to produce the target protein for a while, thus stimulating the production of antibodies and activation of killer T-cells. Although DNA vaccines are used in the veterinary field, none of them have been administered to humans. However, Inovio from the United States and Genexine from Korea are under trial [<xref rid="REF18" ref-type="bibr">18</xref>].</p><p>mRNA-Based Vaccines</p><p>mRNA vaccines induce the cell to produce antigen proteins coded by the mRNA where it is carried by liposomes as nanoparticles, unlike DNA-based vaccines. Pfizer from the United States, Moderna from the United States, Arcturus Ther from Singapore, and CureVac from Germany have been administered to the population after passing clinical trials successfully [<xref rid="REF18" ref-type="bibr">18</xref>]. In addition, an inhaled form of vaccine from the University of Oxford, UK, has not yet reached phase III trial.</p><p>Vaccines Based on Viral Vectors</p><p>The DNA coding for the spike protein is inserted into the virus as the virus has the ability to induce immunity by delivering mRNA into the cells. Sputnik from Russia, Covishield from India, Johnson &amp; Johnson from the United States, and Ad5-nCoV use viral vectors to target spike protein [<xref rid="REF8" ref-type="bibr">8</xref>].</p><p>Efficacy of COVID-19 vaccines</p><p>Vaccine efficacy is generally reported as relative risk reduction (RRR) which uses the relative risk (RR) that uses the ratio of attack rates with or without a vaccine, whereas absolute risk reduction (ARR) uses the whole population. However, ARR tends to be ignored as it gives much less effect than RRR. Efficacy provides the RRR of 95% for the Pfizer-BioNTech, 94% for Moderna-NIH, 91% for Gamaleya, 67% for Johnson &amp; Johnson, and 67% for AstraZeneca Oxford vaccines. However, the spectrum entirely changes when the effectiveness of a vaccine is calculated in terms of the number needed to vaccinate (NNV) to prevent one more case of COVID-19, with 81 for Moderna-NIH, 78 for AstraZeneca Oxford, 108 for Gamaleya, 84 for Johnson &amp; Johnson, and 119 for Pfizer-BioNTech vaccines [<xref rid="REF19" ref-type="bibr">19</xref>].</p><p>BNT162b2/Pfizer/BioNTech was the first vaccine approved by the European Medicines Agency against COVID-19 which is administered intramuscularly after dilution in a cycle of two doses 21 days apart [<xref rid="REF20" ref-type="bibr">20</xref>,<xref rid="REF21" ref-type="bibr">21</xref>]. Preclinical data include the investigation of immunogenicity and antiviral properties in mice and non-human primates, which proved that the BNT162b2 vaccine protected the lungs of immunized rhesus macaques from COVID-19 [<xref rid="REF22" ref-type="bibr">22</xref>]. In a phase I/II study, where BNT162b2 was administered to adults, the geometric mean concentrations of RBD-binding immunoglobulin G (IgG) were high after 21 days of the first dose (534-1778 U/mL) when compared to the human convalescent serum (HCS 602 U/mL) after 14 days of the infection confirmed by polymerase chain reaction (PCR). This vaccine showed 95% efficacy and proved that early protection occurs 12 days after the first dose. Another study was performed to evaluate the humoral and adaptive immune response for BNT162b1 from phase I/II studies, in which GMC of anti-RBD antibodies were more in vaccinated individuals (3,920-18,289 U/mL) when compared to HCS (602 U/mL) [<xref rid="REF23" ref-type="bibr">23</xref>,<xref rid="REF24" ref-type="bibr">24</xref>]. Further, the efficacy of the vaccine against variants was also tested which shows high neutralizing capacity in all variants, with increased CD4+ and CD8+ RBD-specific T-lymphocytes [<xref rid="REF25" ref-type="bibr">25</xref>]. However, BNT162b2 was recommended as it is associated with lower incidence and severity of systemic complications when compared to BNT162b1. A two-dose regimen of BNT162b2 conferred 95% efficacy against COVID-19 in a study conducted among 43,448 participants who were injected with the COVID-19 vaccine and saline placebo. Though the efficacy after the first dose was only 51%, it gradually increased to 91% within the first seven days of the second dose [<xref rid="REF26" ref-type="bibr">26</xref>]. The vaccine efficacy among participants with hypertension also yielded an efficacy of 94.6%, consistent with other participants [<xref rid="REF27" ref-type="bibr">27</xref>]. Another study among&#160;healthcare workers in Israel to evaluate the efficacy was found to be 30% in 1-14 days and 75% in 15-28 days [<xref rid="REF27" ref-type="bibr">27</xref>-<xref rid="REF29" ref-type="bibr">29</xref>]. In another study, the efficacy in preventing hospitalization after severe infection was found to be 80%, and a single dose helped in preventing death by 85%&#160;[<xref rid="REF30" ref-type="bibr">30</xref>-<xref rid="REF32" ref-type="bibr">32</xref>].</p><p>The Sputnik V vaccine is a vector vaccine based on adenovirus DNA administered over a course of two days, initially produced in Russia. In the previous study, the efficacy of the Sputnik vaccine with two vector components, namely, recombinant adenovirus type 26 (rAd26) and adenovirus type 5 (rAd5), manufactured in two formulations - frozen (0.5 mL) and lyophilized (1 mL of sterile water per dose) was demonstrated. There was increased production of CD4+ and CD8+ after administration of the frozen form than of the lyophilized form, and there was also increased production of interferon-gamma (IFN-&#947;) in all vaccinated individuals. The titer of neutralizing antibodies matches the convalescent human serum of those who recovered from recent infection [<xref rid="REF33" ref-type="bibr">33</xref>]. The phase 3 trial of the Sputnik vaccine gives an efficacy of 91.6% (confidence interval (CI) = 95%), and, interestingly, it was 91.8% for older adults above 60 years. However, initially, the efficacy was 73.6% till 21 days after the first dose [<xref rid="REF33" ref-type="bibr">33</xref>,<xref rid="REF34" ref-type="bibr">34</xref>]. In another study where the vaccine was administered in older individuals after the first dose, the efficacy was found to be 78.6% of laboratory-confirmed SARS-CoV-2 infections, 94% in hospitalization, and 93% in preventing death among them, thus delaying the second dose can be followed to increase neutralizing antibodies [<xref rid="REF35" ref-type="bibr">35</xref>]. The vaccine resists the variants of the COVID-19 virus with a 6.1-fold reduction in the neutralizing activity [<xref rid="REF36" ref-type="bibr">36</xref>].</p><p>Covishield/AZD1222/ChAdOx1 is a viral vector intramuscular vaccine manufactured by the Serum Institute of India and is administered in two doses. In a study among 52 healthy individuals who received the second dose after 56 days of the first dose, there were no systemic reactions such as pyrexia as in the first dose [<xref rid="REF37" ref-type="bibr">37</xref>-<xref rid="REF39" ref-type="bibr">39</xref>]. After the first dose, discrete populations of T-cells, B-cells, and natural killer (NK) cells were detected. There was no sex difference and association between the age and magnitude response in this study among individuals aged from 18 to 55 years. The IgG spike was similar to that of plasma from convalescent patients with SARS-CoV-2. The CD4+ and CD8+ secrete antigen-specific cytokines with CD8+ T-cells expressing CD107a, which is a degranulation marker, indicating its cytotoxic effect after vaccination. However, the predominant cytokines were IFN-&#947; and CD8+ cells [<xref rid="REF38" ref-type="bibr">38</xref>]. The levels of anti-spike IgG were found to be lower when the individuals received half-booster doses; however, it was increased to 10-fold when they received prime booster doses [<xref rid="REF38" ref-type="bibr">38</xref>,<xref rid="REF39" ref-type="bibr">39</xref>]. The total antigen-specific T-cell response was increased after 14 days of vaccination [<xref rid="REF37" ref-type="bibr">37</xref>]. The second dose either given after 28 days or 56 days after the first shot provides a similar response in producing the antibodies [<xref rid="REF39" ref-type="bibr">39</xref>]. Preclinical studies in Rhesus macaques prevent SARS-CoV-2-mediated pneumonia [<xref rid="REF40" ref-type="bibr">40</xref>]. After administration of Covishield with booster dose in older adults, microneutralization assay peaked by day 42, the antibody titers were not raised after the booster dose in all age groups, and the immunization response in older adults was very similar to young adults. The anti-spike IgG levels correlate with neutralizing antibody titers for all age groups (18-55, 56-69, 70, and older) [<xref rid="REF41" ref-type="bibr">41</xref>]. Another study with 23,848 participants across different parts of the world such as the UK, Brazil, and South Africa was conducted to estimate the efficacy. Interestingly, those who received two standard doses had lesser efficacy (70.4%) than those who received a low dose (2.2 &#215; 1,010 viral particles) vaccine at the first dose followed by the standard booster dose (5 &#215; 1,010 viral particles) (90%). The second dose within six weeks of the first dose provides less efficacy (53.4%) than the one with more than six weeks between the first and second dose (65.4%). Thus, delaying the second dose helps in increasing the efficacy, as well as overcoming the low availability of vaccines in this pandemic situation [<xref rid="REF42" ref-type="bibr">42</xref>].</p><p>Covaxin/BBV152 is an inactivated virus-based COVID-19 vaccine formulated by Bharat Biotech and administered intramuscularly in two doses similar to any other COVID-19 vaccine. In a study with 375 healthy individuals, the vaccine (3 &#181;g and 6 &#181;g with IMBG) was given randomly to evaluate the immune response and efficacy. The most common adverse effects reported were pain in the injection site (5%), fatigue (3%), and headache (3%). The IgG titers were increased after the second dose, and the efficacy was 87.9% with 3 &#181;g and 91.9% with 6 &#181;g, thus IgG titers do not have any effect on the concentration [<xref rid="REF43" ref-type="bibr">43</xref>]. However, both the doses elicit CD3+, CD4+, and CD8+ leading to IFN-&#947; production, and the neutralizing antibodies remained elevated for three months after the second vaccination. In the follow-up study with 380 participants, the neutralizing antibody titers were similar to the convalescent serum, and the same results were obtained in other studies [<xref rid="REF31" ref-type="bibr">31</xref>,<xref rid="REF44" ref-type="bibr">44</xref>,<xref rid="REF45" ref-type="bibr">45</xref>].</p><p>The Janssen/Johnson &amp; Johnson is another viral vector-based vaccine that requires only a single dose. The first dose of the Johnson &amp; Johnson vaccine provides an efficacy of 76.7% after 14 days of administration of the first dose. However, a phase 3 trial showed an efficacy of 66.9% after 14 days and 66.1% after 28 days of vaccination. The efficacy of preventing severe infection was 76.7% after 14 days and 85.4% after 28 days which is quite high [<xref rid="REF46" ref-type="bibr">46</xref>,<xref rid="REF47" ref-type="bibr">47</xref>]. However, other studies reveal that it was 66% effective in preventing symptomatic COVID-19, 85% in severe COVID-19, and 100% in preventing hospitalization or death [<xref rid="REF48" ref-type="bibr">48</xref>,<xref rid="REF49" ref-type="bibr">49</xref>].</p><p>COVID-19 vaccines against variants of coronavirus</p><p>The virus mutations have resulted in variants such as B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617 (delta), and the newer omicron (B.1.1.7), which has enhanced transmissibility and fatality rates [<xref rid="REF50" ref-type="bibr">50</xref>-<xref rid="REF52" ref-type="bibr">52</xref>]. The S genes of B.1.351 and P.1 have various mutations and that might be the reason for re-infection by vanishing neutralizing antibodies formed during infection by the alpha variant [<xref rid="REF53" ref-type="bibr">53</xref>,<xref rid="REF54" ref-type="bibr">54</xref>]. The recent delta variant is characterized by spike protein mutations. P681R is at the S1-S2 cleavage site, and this variant has replication at its peak with higher transmissibility [<xref rid="REF55" ref-type="bibr">55</xref>]. The first case of the recent omicron (B.1.1.529) with mutations in the RBD and NTD first emerged in South Africa in November 2021. The risk of reinfection is 5.4 times greater with omicron than that of the delta variant [<xref rid="REF56" ref-type="bibr">56</xref>,<xref rid="REF57" ref-type="bibr">57</xref>]. The emergence of these variants globally is illustrated in Figure <xref rid="FIG1" ref-type="fig">1</xref>.</p><fig position="anchor" fig-type="figure" id="FIG1" orientation="portrait"><label>Figure 1</label><caption><title>The earliest documented samples of COVID-19 variants according to the World Health Organization.</title><p>Yellow depicts the alpha variant, blue depicts the beta variant, green depicts the gamma variant, and red indicates the delta variant and their emergence in the respective countries.</p><p>COVID-19: coronavirus disease 2019</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0014-00000024927-i01.jpg"/></fig><p>The efficacy of single doses of BNT162b2 and ChAdOx1nCoV-19 vaccines against the delta variant is approximately 36% and 30%, respectively. However, the second dose increases the efficacy to 88% and 67%, respectively. A study from Scotland revealed that the efficacy of Covaxin is 81% against the alpha variant and 61% against the delta variant [<xref rid="REF58" ref-type="bibr">58</xref>]. The efficacy of Covaxin against the delta variant is around 65% according to a phase 3 trial study [<xref rid="REF59" ref-type="bibr">59</xref>]. The efficacy of Pfizer and AstraZeneca after the second dose was found to be 78% and 61%, respectively [<xref rid="REF60" ref-type="bibr">60</xref>]. However, Pfizer-BioTech and Oxford-AstraZeneca vaccines were highly efficacious against delta variants but dropped over time [<xref rid="REF61" ref-type="bibr">61</xref>]. Alpha variants have a 1.8-2-fold reduction in neutralizing antibodies of Moderna, Sputnik, and Novovax vaccines. The neutralizing capacity for the P.1 variant among vaccinated individuals was reduced by 6.7 for the Pfizer vaccine and 4.5 for the Moderna vaccine [<xref rid="REF62" ref-type="bibr">62</xref>]. Delta variants have a 7-10 fold reduction in neutralizing antibody levels of Pfizer, Moderna, and Sputnik, and a 2-3-fold reduction in the case of Covishield and Covaxin; however, the sample study with Johnson and Johnson showed that it neutralizes the delta variant similar to Sputnik. However, Sputnik against B.1.351 variant showed a 6.1-fold reduction in neutralizing antibodies [<xref rid="REF63" ref-type="bibr">63</xref>]. In another study, sera from&#160;AstraZeneca recipients showed a 4.1-32.5-fold reduction in neutralizing activity against B.1.351 [<xref rid="REF64" ref-type="bibr">64</xref>]. However, the reduction in the neutralizing antibodies in the sera of individuals receiving Moderna and BioNTech vaccines was 6.5-8.6-fold [<xref rid="REF62" ref-type="bibr">62</xref>]. ZyCov-D is another DNA vaccine that is claimed to be effective against the delta variant in clinical trials [<xref rid="REF65" ref-type="bibr">65</xref>]. The efficacy of these vaccines and the reduction in the neutralizing capacity of COVID-19 vaccines against variants of COVID-19 are presented in Table <xref rid="TAB1" ref-type="table">1</xref> and Table <xref rid="TAB2" ref-type="table">2</xref>. Vaccinated people affected with the alpha variant had a lower viral load, whereas vaccinated individuals infected with the delta variant had a higher viral load. Thus, irrespective of the vaccine administered, the efficacy is reduced against the delta virus, but still effective in reducing fatality. Until October 2021, globally, 676 crore doses were given and 288 crore individuals were fully vaccinated, that is, 36.9% of the population. In India, 99.7 crore doses were administered to 29.2 crore individuals (21.1%) who are fully vaccinated [<xref rid="REF66" ref-type="bibr">66</xref>]. The research is still ongoing regarding vaccine efficacy against omicron; however, researchers have found that two doses of the Pfizer vaccine provide 70% infection against hospitalization and 33% against infection [<xref rid="REF67" ref-type="bibr">67</xref>]. As the efficacy wanes over time, researchers are insisting on having a third dose/booster dose which helps in boosting the efficacy. Recent studies have focused on the combination of booster doses for better efficacy. There was no increase in the efficacy against omicron even after the two doses of AstraZeneca, and this variant reduced the efficacy of Pfizer/Moderna to 10% even after two doses which increased to 40-50% and the effectiveness against hospitalization also increased to 88% after the booster dose [<xref rid="REF68" ref-type="bibr">68</xref>]. The booster dose increases the neutralizing antibody titers by 25-fold with the Pfizer vaccine [<xref rid="REF69" ref-type="bibr">69</xref>]. The recent study of&#160;vaccine&#160;BNT162b2 among the pediatric population (5-11 years) showed 95% efficacy after two doses [<xref rid="REF70" ref-type="bibr">70</xref>]. Because the efficacy of vaccines against the omicron variant is under investigation, the data available to date is presented in Table <xref rid="TAB3" ref-type="table">3</xref>; however, this might change as studies are published.</p><table-wrap position="float" id="TAB1" orientation="portrait"><label>Table 1</label><caption><title>The efficacy of the first and second doses of COVID-19 vaccines against alpha and delta variants.</title><p>COVID-19: coronavirus disease 2019; CI: confidence interval</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Authors
</td><td rowspan="1" colspan="1">
Vaccination doses
</td><td rowspan="1" colspan="1">
Alpha variant (95% CI)
</td><td rowspan="1" colspan="1">
Delta variant (95% CI)
</td><td rowspan="1" colspan="1">
Omicron
</td></tr><tr><td rowspan="3" colspan="1">
Polack et al. [<xref rid="REF26" ref-type="bibr">26</xref>]
</td><td colspan="4" rowspan="1">
BNT162b2
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Dose 1
</td><td rowspan="1" colspan="1">
51%
</td><td rowspan="1" colspan="1">
-
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
91%
</td><td rowspan="1" colspan="1">
-
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr style="background-color:#ccc"><td rowspan="3" colspan="1">
Chung et al. [<xref rid="REF32" ref-type="bibr">32</xref>]
</td><td colspan="4" rowspan="1">
Moderna
</td></tr><tr><td rowspan="1" colspan="1">
Dose 1
</td><td rowspan="1" colspan="1">
71%
</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">
No data
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
91%
</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">
No data
</td></tr><tr><td rowspan="1" colspan="1">&#160;</td><td colspan="4" rowspan="1">
Covaxin
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Sheikh et al. [<xref rid="REF58" ref-type="bibr">58</xref>]
</td><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
81%
</td><td rowspan="1" colspan="1">
61%
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr><td rowspan="1" colspan="1">
Ella et al. [<xref rid="REF59" ref-type="bibr">59</xref>]
</td><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
-
</td><td rowspan="1" colspan="1">
65%
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr style="background-color:#ccc"><td rowspan="7" colspan="1">
Lopez Bernal et al. [<xref rid="REF60" ref-type="bibr">60</xref>]
</td><td colspan="4" rowspan="1">
ChAdOx1 nCoV-19
</td></tr><tr><td rowspan="1" colspan="1">
Dose 1
</td><td rowspan="1" colspan="1">
48.7 (45.2&#8211;51.9)
</td><td rowspan="1" colspan="1">
30.0 (24.3&#8211;35.3)
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
74.5 (68.4&#8211;79.4)
</td><td rowspan="1" colspan="1">
67.0 (61.3&#8211;71.8)
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr><td colspan="4" rowspan="1">
Pfizer
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
92
</td><td rowspan="1" colspan="1">
78 (90 days)
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr><td colspan="4" rowspan="1">
AstraZeneca
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
69
</td><td rowspan="1" colspan="1">
61 (90 days)
</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="3" colspan="1">
Lopez Bernal et al. [<xref rid="REF60" ref-type="bibr">60</xref>]
</td><td colspan="4" rowspan="1">
BNT162b2
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Dose 1
</td><td rowspan="1" colspan="1">
47.5 (41.6&#8211;52.8)
</td><td rowspan="1" colspan="1">
35.6 (22.7&#8211;46.4)
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
93.7 (91.6&#8211;95.3)
</td><td rowspan="1" colspan="1">
88.0 (85.3&#8211;90.1)
</td><td rowspan="1" colspan="1">
No data
</td></tr><tr style="background-color:#ccc"><td rowspan="2" colspan="1">
Collie et al. [<xref rid="REF67" ref-type="bibr">67</xref>]
</td><td colspan="4" rowspan="1">
Pfizer
</td></tr><tr><td rowspan="1" colspan="1">
Dose 2
</td><td rowspan="1" colspan="1">
-
</td><td rowspan="1" colspan="1">
-
</td><td rowspan="1" colspan="1">
70
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB2" orientation="portrait"><label>Table 2</label><caption><title>Reduction in the neutralizing capacity of COVID-19 vaccines against alpha, beta, delta, and omicron variants of COVID-19.</title><p>COVID-19: coronavirus disease 2019; UI: under investigation</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
COVID-19 vaccines
</td><td rowspan="1" colspan="1">
Alpha
</td><td rowspan="1" colspan="1">
Beta
</td><td rowspan="1" colspan="1">
Delta
</td><td rowspan="1" colspan="1">
Omicron
</td></tr><tr><td rowspan="1" colspan="1">
Covaxin
</td><td rowspan="1" colspan="1">
Unaffected
</td><td rowspan="1" colspan="1">
3
</td><td rowspan="1" colspan="1">
3
</td><td rowspan="1" colspan="1">
UI
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Covishield
</td><td rowspan="1" colspan="1">
2.5&#8211;9
</td><td rowspan="1" colspan="1">
0&#8211;31
</td><td rowspan="1" colspan="1">
2
</td><td rowspan="1" colspan="1">
UI
</td></tr><tr><td rowspan="1" colspan="1">
Pfizer
</td><td rowspan="1" colspan="1">
0&#8211;4
</td><td rowspan="1" colspan="1">
1&#8211;4
</td><td rowspan="1" colspan="1">
7&#8211;10
</td><td rowspan="1" colspan="1">
4&#8211;6 lower than wild type
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Moderna
</td><td rowspan="1" colspan="1">
0&#8211;2
</td><td rowspan="1" colspan="1">
1&#8211;28
</td><td rowspan="1" colspan="1">
7
</td><td rowspan="1" colspan="1">
UI
</td></tr><tr><td rowspan="1" colspan="1">
Sputnik
</td><td rowspan="1" colspan="1">
0
</td><td rowspan="1" colspan="1">
7
</td><td rowspan="1" colspan="1">
-
</td><td rowspan="1" colspan="1">
UI
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Johnson &amp; Johnson
</td><td rowspan="1" colspan="1">
&lt;1
</td><td rowspan="1" colspan="1">
5&#8211;10
</td><td rowspan="1" colspan="1">
-
</td><td rowspan="1" colspan="1">
UI
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB3" orientation="portrait"><label>Table 3</label><caption><title>Efficacy of COVID-19 vaccines against the omicron variant.</title><p>Because the efficacy of vaccines against the omicron variant is under investigation, the data available to date has been listed in the table which might change when more studies are published.</p><p>COVID-19: coronavirus disease 2019</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Vaccines</td><td rowspan="1" colspan="1">Dose</td><td rowspan="1" colspan="1">Efficacy against hospitalization</td><td rowspan="1" colspan="1">Efficacy against infection</td></tr><tr><td rowspan="2" colspan="1">Pfizer</td><td rowspan="1" colspan="1">Dose 2</td><td rowspan="1" colspan="1">70%</td><td rowspan="1" colspan="1">30&#8211;40%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Booster dose</td><td rowspan="1" colspan="1">88%</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Moderna</td><td rowspan="1" colspan="1">Dose 2</td><td rowspan="1" colspan="1">78%</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">Booster dose</td><td rowspan="1" colspan="1">88%</td><td rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Though we are not free from this pandemic yet, vaccines have really helped to overcome the fatality globally. Hence, the main focus now should be on vaccine availability and its distribution globally. More than anything, it should reach everyone equally. It would be appreciable if vaccines are developed for newborns and children. Vaccine production is a lengthy, tedious process, and preparing it during a pandemic leads to a financial crisis and a doubtful immune response. In addition, the mutated variants make the job really challenging more than the population and mass vaccine production. Despite the challenges, we hope that the pandemic ends by conquering mass immunity by administering vaccines to every individual at a faster rate.</p></sec></body><back><fn-group content-type="competing-interests"><fn fn-type="COI-statement"><p>The authors have declared that no competing interests exist.</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Evidence supporting a zoonotic origin of human coronavirus strain NL63</article-title><source>J Virol</source><person-group><name name-style="western"><surname>Huynh</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B</given-names></name><etal/></person-group><fpage>12816</fpage><lpage>12825</lpage><volume>86</volume><year>2012</year><pub-id pub-id-type="pmid">22993147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00906-12</pub-id><pub-id pub-id-type="pmcid">PMC3497669</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg Microbes Infect</source><person-group><name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name><name name-style="western"><surname>Kok</surname><given-names>KH</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H</given-names></name><name name-style="western"><surname>To</surname><given-names>KK</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></name></person-group><fpage>221</fpage><lpage>236</lpage><volume>9</volume><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1080/22221751.2020.1719902">http://dx.doi.org/10.1080/22221751.2020.1719902</uri><pub-id pub-id-type="pmid">31987001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2020.1719902</pub-id><pub-id pub-id-type="pmcid">PMC7067204</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Lu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><fpage>565</fpage><lpage>574</lpage><volume>395</volume><year>2020</year><pub-id pub-id-type="pmid">32007145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>COVID-19 infection: origin, transmission, and characteristics of human coronaviruses</article-title><source>J Adv Res</source><person-group><name name-style="western"><surname>Shereen</surname><given-names>MA</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>A</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>N</given-names></name><name name-style="western"><surname>Siddique</surname><given-names>R</given-names></name></person-group><fpage>91</fpage><lpage>98</lpage><volume>24</volume><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1016/j.jare.2020.03.005">http://dx.doi.org/10.1016/j.jare.2020.03.005</uri><pub-id pub-id-type="pmid">32257431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2020.03.005</pub-id><pub-id pub-id-type="pmcid">PMC7113610</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>COVID-19: the first documented coronavirus pandemic in history</article-title><source>Biomed J</source><person-group><name name-style="western"><surname>Liu</surname><given-names>YC</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>RL</given-names></name><name name-style="western"><surname>Shih</surname><given-names>SR</given-names></name></person-group><fpage>328</fpage><lpage>333</lpage><volume>43</volume><year>2020</year><pub-id pub-id-type="pmid">32387617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bj.2020.04.007</pub-id><pub-id pub-id-type="pmcid">PMC7199674</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title><source>Nat Rev Microbiol</source><person-group><name name-style="western"><surname>Harvey</surname><given-names>WT</given-names></name><name name-style="western"><surname>Carabelli</surname><given-names>AM</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B</given-names></name><etal/></person-group><fpage>409</fpage><lpage>424</lpage><volume>19</volume><year>2021</year><pub-id pub-id-type="pmid">34075212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-021-00573-0</pub-id><pub-id pub-id-type="pmcid">PMC8167834</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Is there a role for childhood vaccination against COVID-19?</article-title><source>Pediatr Allergy Immunol</source><person-group><name name-style="western"><surname>Eberhardt</surname><given-names>CS</given-names></name><name name-style="western"><surname>Siegrist</surname><given-names>CA</given-names></name></person-group><fpage>9</fpage><lpage>16</lpage><volume>32</volume><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1111/pai.13401">http://dx.doi.org/10.1111/pai.13401</uri><pub-id pub-id-type="pmid">33113210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pai.13401</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>SARS-CoV-2 vaccines in development</article-title><source>Nature</source><person-group><name name-style="western"><surname>Krammer</surname><given-names>F</given-names></name></person-group><fpage>516</fpage><lpage>527</lpage><volume>586</volume><year>2020</year><pub-id pub-id-type="pmid">32967006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2798-3</pub-id></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>A SARS-CoV-2 mRNA vaccine - preliminary report</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Schaefer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Sharkova</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nickolaus</surname><given-names>T</given-names></name></person-group><fpage>1191</fpage><volume>383</volume><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1056/nejmc2026616">http://dx.doi.org/10.1056/nejmc2026616</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2026616</pub-id><pub-id pub-id-type="pmid">32813941</pub-id></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Viral vectors as vaccine platforms: from immunogenicity to impact</article-title><source>Curr Opin Immunol</source><person-group><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Rollier</surname><given-names>CS</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hill</surname><given-names>AV</given-names></name><name name-style="western"><surname>Dorrell</surname><given-names>L</given-names></name></person-group><fpage>47</fpage><lpage>54</lpage><volume>41</volume><year>2016</year><pub-id pub-id-type="pmid">27286566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2016.05.014</pub-id></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Zhu</surname><given-names>FC</given-names></name><name name-style="western"><surname>Li</surname><given-names>YH</given-names></name><name name-style="western"><surname>Guan</surname><given-names>XH</given-names></name><etal/></person-group><fpage>1845</fpage><lpage>1854</lpage><volume>395</volume><year>2020</year><pub-id pub-id-type="pmid">32450106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="book"><article-title>Faculty Opinions recommendation of "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV- 2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"</article-title><person-group><name name-style="western"><surname>Koh</surname><given-names>G</given-names></name></person-group><fpage>2020</fpage><publisher-loc>London, UK</publisher-loc><publisher-name>Faculty Opinions</publisher-name><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.3410/f.738355504.793576875">http://dx.doi.org/10.3410/f.738355504.793576875</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id><pub-id pub-id-type="pmid">32702298</pub-id></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="website"><article-title>Safety and immunogenicity study of inactivated vaccine for prevention of SARS-CoV-2 infection (COVID-19)</article-title><date-in-citation content-type="access-date"><month>9</month><year>2021</year></date-in-citation><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04383574">https://clinicaltrials.gov/ct2/show/NCT04383574</uri></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="website"><article-title>Clinical trial of efficacy and safety of Sinovac's adsorbed COVID-19 (inactivated) vaccine in healthcare professionals (PROFISCOV)</article-title><date-in-citation content-type="access-date"><month>9</month><year>2021</year></date-in-citation><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04456595">https://clinicaltrials.gov/ct2/show/NCT04456595</uri></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>The potential danger of suboptimal antibody responses in COVID-19</article-title><source>Nat Rev Immunol</source><person-group><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><fpage>339</fpage><lpage>341</lpage><volume>20</volume><year>2020</year><pub-id pub-id-type="pmid">32317716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0321-6</pub-id><pub-id pub-id-type="pmcid">PMC7187142</pub-id></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies</article-title><source>Nat Microbiol</source><person-group><name name-style="western"><surname>Lee</surname><given-names>WS</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>DeKosky</surname><given-names>BJ</given-names></name></person-group><fpage>1185</fpage><lpage>1191</lpage><volume>5</volume><year>2020</year><pub-id pub-id-type="pmid">32908214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-00789-5</pub-id><pub-id pub-id-type="pmcid">PMC12103240</pub-id></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="website"><article-title>SCB-2019 as COVID-19 vaccine</article-title><date-in-citation content-type="access-date"><month>9</month><year>2021</year></date-in-citation><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04405908">https://clinicaltrials.gov/ct2/show/NCT04405908</uri></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>COVID-19 vaccines: where we stand and challenges ahead</article-title><source>Cell Death Differ</source><person-group><name name-style="western"><surname>Forni</surname><given-names>G</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name></person-group><fpage>626</fpage><lpage>639</lpage><volume>28</volume><year>2021</year><pub-id pub-id-type="pmid">33479399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-020-00720-9</pub-id><pub-id pub-id-type="pmcid">PMC7818063</pub-id></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room</article-title><source>Lancet Microbe</source><person-group><name name-style="western"><surname>Olliaro</surname><given-names>P</given-names></name><name name-style="western"><surname>Torreele</surname><given-names>E</given-names></name><name name-style="western"><surname>Vaillant</surname><given-names>M</given-names></name></person-group><fpage>0</fpage><lpage>80</lpage><volume>2</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(21)00069-0</pub-id><pub-id pub-id-type="pmcid">PMC8057721</pub-id><pub-id pub-id-type="pmid">33899038</pub-id></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>European Medicines Agency. Assessment report</article-title><date-in-citation content-type="access-date"><month>9</month><year>2021</year></date-in-citation><fpage>2021</fpage><lpage>2022</lpage><volume>[No title]</volume><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf">https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf</uri></element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>European Medicines Agency. Summary of product characteristics</article-title><date-in-citation content-type="access-date"><month>9</month><year>2021</year></date-in-citation><fpage>2021</fpage><lpage>2022</lpage><volume>[No title]</volume><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf">https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf</uri></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates</article-title><source>bioRxiv</source><person-group><name name-style="western"><surname>Vogel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Kanevsky</surname><given-names>I</given-names></name><name name-style="western"><surname>Che</surname><given-names>Y</given-names></name></person-group><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1.abstract">https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1.abstract</uri></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Phase&#160;I/II study of COVID-19 RNA vaccine BNT162b1 in adults</article-title><source>Nature</source><person-group><name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><etal/></person-group><fpage>589</fpage><lpage>593</lpage><volume>586</volume><year>2020</year><pub-id pub-id-type="pmid">32785213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2639-4</pub-id></element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses</article-title><source>Nature</source><person-group><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Muik</surname><given-names>A</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><etal/></person-group><fpage>594</fpage><lpage>599</lpage><volume>586</volume><year>2020</year><pub-id pub-id-type="pmid">32998157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2814-7</pub-id></element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera</article-title><source>bioRxiv</source><person-group><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1101/2021.01.27.427998">http://dx.doi.org/10.1101/2021.01.27.427998</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01270-4</pub-id><pub-id pub-id-type="pmid">33558724</pub-id></element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><etal/></person-group><fpage>2603</fpage><lpage>2615</lpage><volume>383</volume><year>2020</year><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Amit</surname><given-names>S</given-names></name><name name-style="western"><surname>Regev-Yochay</surname><given-names>G</given-names></name><name name-style="western"><surname>Afek</surname><given-names>A</given-names></name><name name-style="western"><surname>Kreiss</surname><given-names>Y</given-names></name><name name-style="western"><surname>Leshem</surname><given-names>E</given-names></name></person-group><fpage>875</fpage><lpage>877</lpage><volume>397</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00448-7</pub-id><pub-id pub-id-type="pmcid">PMC7906709</pub-id><pub-id pub-id-type="pmid">33610193</pub-id></element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Vasileiou</surname><given-names>E</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>CR</given-names></name><name name-style="western"><surname>Shi</surname><given-names>T</given-names></name><etal/></person-group><fpage>1646</fpage><lpage>1657</lpage><volume>397</volume><year>2021</year><pub-id pub-id-type="pmid">33901420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00677-2</pub-id><pub-id pub-id-type="pmcid">PMC8064669</pub-id></element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>An mRNA vaccine against SARS-CoV-2 - preliminary report</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></name><etal/></person-group><fpage>1920</fpage><lpage>1931</lpage><volume>383</volume><year>2020</year><pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>B</given-names></name><name name-style="western"><surname>Foulds</surname><given-names>KE</given-names></name><etal/></person-group><fpage>1544</fpage><lpage>1555</lpage><volume>383</volume><year>2020</year><pub-id pub-id-type="pmid">32722908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2024671</pub-id><pub-id pub-id-type="pmcid">PMC7449230</pub-id></element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="journal"><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><etal/></person-group><fpage>403</fpage><lpage>416</lpage><volume>384</volume><year>2021</year><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="REF32"><label>32</label><element-citation publication-type="journal"><article-title>Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study</article-title><source>BMJ</source><person-group><name name-style="western"><surname>Chung</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Nasreen</surname><given-names>S</given-names></name><etal/></person-group><fpage>0</fpage><volume>374</volume><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://papers.ssrn.com/abstract">https://papers.ssrn.com/abstract</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n1943</pub-id><pub-id pub-id-type="pmcid">PMC8377789</pub-id><pub-id pub-id-type="pmid">34417165</pub-id></element-citation></ref><ref id="REF33"><label>33</label><element-citation publication-type="journal"><article-title>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></name><etal/></person-group><fpage>887</fpage><lpage>897</lpage><volume>396</volume><year>2020</year><pub-id pub-id-type="pmid">32896291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id></element-citation></ref><ref id="REF34"><label>34</label><element-citation publication-type="journal"><article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></name><etal/></person-group><fpage>671</fpage><lpage>681</lpage><volume>397</volume><year>2021</year><pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></element-citation></ref><ref id="REF35"><label>35</label><element-citation publication-type="journal"><article-title>Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants</article-title><source>PLoS Comput Biol</source><person-group><name name-style="western"><surname>Yin</surname><given-names>R</given-names></name><name name-style="western"><surname>Guest</surname><given-names>JD</given-names></name><name name-style="western"><surname>Taherzadeh</surname><given-names>G</given-names></name><name name-style="western"><surname>Gowthaman</surname><given-names>R</given-names></name><name name-style="western"><surname>Mittra</surname><given-names>I</given-names></name><name name-style="western"><surname>Quackenbush</surname><given-names>J</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>BG</given-names></name></person-group><fpage>0</fpage><volume>17</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1009380</pub-id><pub-id pub-id-type="pmcid">PMC8448325</pub-id><pub-id pub-id-type="pmid">34491988</pub-id></element-citation></ref><ref id="REF36"><label>36</label><element-citation publication-type="journal"><article-title>Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina</article-title><source>EClinicalMedicine</source><person-group><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>S</given-names></name><name name-style="western"><surname>Olszevicki</surname><given-names>S</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>M</given-names></name><etal/></person-group><fpage>101126</fpage><volume>40</volume><year>2021</year><pub-id pub-id-type="pmid">34541480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.101126</pub-id><pub-id pub-id-type="pmcid">PMC8435263</pub-id></element-citation></ref><ref id="REF37"><label>37</label><element-citation publication-type="journal"><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><etal/></person-group><fpage>467</fpage><lpage>478</lpage><volume>396</volume><year>2020</year><pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></element-citation></ref><ref id="REF38"><label>38</label><element-citation publication-type="journal"><article-title>T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial</article-title><source>Nat Med</source><person-group><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>JR</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><etal/></person-group><fpage>270</fpage><lpage>278</lpage><volume>27</volume><year>2021</year><pub-id pub-id-type="pmid">33335323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01194-5</pub-id></element-citation></ref><ref id="REF39"><label>39</label><element-citation publication-type="journal"><article-title>Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses</article-title><source>Nat Med</source><person-group><name name-style="western"><surname>Barrett</surname><given-names>JR</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name name-style="western"><surname>Dold</surname><given-names>C</given-names></name><etal/></person-group><fpage>279</fpage><lpage>288</lpage><volume>27</volume><year>2021</year><pub-id pub-id-type="pmid">33335322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01179-4</pub-id></element-citation></ref><ref id="REF40"><label>40</label><element-citation publication-type="journal"><article-title>ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title><source>bioRxiv</source><person-group><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name><etal/></person-group><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1101/2020.05.13.093195">http://dx.doi.org/10.1101/2020.05.13.093195</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-03099-2</pub-id><pub-id pub-id-type="pmid">33469217</pub-id></element-citation></ref><ref id="REF41"><label>41</label><element-citation publication-type="journal"><article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Ramasamy</surname><given-names>MN</given-names></name><name name-style="western"><surname>Minassian</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><etal/></person-group><fpage>1979</fpage><lpage>1993</lpage><volume>396</volume><year>2021</year><pub-id pub-id-type="pmid">33220855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32466-1</pub-id><pub-id pub-id-type="pmcid">PMC7674972</pub-id></element-citation></ref><ref id="REF42"><label>42</label><element-citation publication-type="journal"><article-title>Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Costa Clemens</surname><given-names>SA</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><etal/></person-group><fpage>881</fpage><lpage>891</lpage><volume>397</volume><year>2021</year><pub-id pub-id-type="pmid">33617777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00432-3</pub-id><pub-id pub-id-type="pmcid">PMC7894131</pub-id></element-citation></ref><ref id="REF43"><label>43</label><element-citation publication-type="journal"><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial</article-title><source>Lancet Infect Dis</source><person-group><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name><etal/></person-group><fpage>637</fpage><lpage>646</lpage><volume>21</volume><year>2021</year><pub-id pub-id-type="pmid">33485468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30942-7</pub-id><pub-id pub-id-type="pmcid">PMC7825810</pub-id></element-citation></ref><ref id="REF44"><label>44</label><element-citation publication-type="journal"><article-title>Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report</article-title><source>medRxiv</source><person-group><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name><etal/></person-group><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1101/2020.12.21.20248643">http://dx.doi.org/10.1101/2020.12.21.20248643</uri></element-citation></ref><ref id="REF45"><label>45</label><element-citation publication-type="journal"><article-title>Durability of responses after SARS-CoV-2 mRNA-1273 vaccination</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Widge</surname><given-names>AT</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></name><etal/></person-group><fpage>80</fpage><lpage>82</lpage><volume>384</volume><year>2021</year><pub-id pub-id-type="pmid">33270381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2032195</pub-id><pub-id pub-id-type="pmcid">PMC7727324</pub-id></element-citation></ref><ref id="REF46"><label>46</label><element-citation publication-type="journal"><article-title>Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19</article-title><source>medRxiv</source><person-group><name name-style="western"><surname>Corchado-Garcia</surname><given-names>J</given-names></name><name name-style="western"><surname>Puyraimond-Zemmour</surname><given-names>D</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>T</given-names></name><etal/></person-group><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1101/2021.04.27.21256193">http://dx.doi.org/10.1101/2021.04.27.21256193</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.32540</pub-id><pub-id pub-id-type="pmcid">PMC8564583</pub-id><pub-id pub-id-type="pmid">34726743</pub-id></element-citation></ref><ref id="REF47"><label>47</label><element-citation publication-type="journal"><article-title>Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A</given-names></name><etal/></person-group><fpage>2187</fpage><lpage>2201</lpage><volume>384</volume><year>2021</year><pub-id pub-id-type="pmid">33882225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2101544</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id></element-citation></ref><ref id="REF48"><label>48</label><element-citation publication-type="website"><article-title>Johnson &amp; Johnson single-shot vaccine 85% effective against severe COVID-19 disease</article-title><date-in-citation content-type="access-date"><month>11</month><year>2021</year></date-in-citation><person-group><name name-style="western"><surname>Salzman</surname><given-names>S</given-names></name></person-group><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://abcnews.go.com/Health/johnson-johnson-single-shot-vaccine-85-effective-severe/story?id=75557358">https://abcnews.go.com/Health/johnson-johnson-single-shot-vaccine-85-effective-severe/story?id=75557358</uri></element-citation></ref><ref id="REF49"><label>49</label><element-citation publication-type="website"><article-title>J&amp;J one-dose Covid vaccine is 66% effective, a weapon but not a knockout punch</article-title><date-in-citation content-type="access-date"><month>11</month><year>2021</year></date-in-citation><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.statnews.com/2021/01/29/jj-one-dose-covid-vaccine-is-66-effective-a-weapon-but-not-a-knockout-punch/">https://www.statnews.com/2021/01/29/jj-one-dose-covid-vaccine-is-66-effective-a-weapon-but-not-a-knockout-punch/</uri></element-citation></ref><ref id="REF50"><label>50</label><element-citation publication-type="journal"><article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England</article-title><source>Science</source><person-group><name name-style="western"><surname>Davies</surname><given-names>NG</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>S</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>RC</given-names></name><etal/></person-group><volume>372</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abg3055</pub-id><pub-id pub-id-type="pmcid">PMC8128288</pub-id><pub-id pub-id-type="pmid">33658326</pub-id></element-citation></ref><ref id="REF51"><label>51</label><element-citation publication-type="journal"><article-title>Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7</article-title><source>Nature</source><person-group><name name-style="western"><surname>Davies</surname><given-names>NG</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>CI</given-names></name><name name-style="western"><surname>Edmunds</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>NP</given-names></name><name name-style="western"><surname>Diaz-Ordaz</surname><given-names>K</given-names></name><name name-style="western"><surname>Keogh</surname><given-names>RH</given-names></name></person-group><fpage>270</fpage><lpage>274</lpage><volume>593</volume><year>2021</year><pub-id pub-id-type="pmid">33723411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03426-1</pub-id><pub-id pub-id-type="pmcid">PMC9170116</pub-id></element-citation></ref><ref id="REF52"><label>52</label><element-citation publication-type="journal"><article-title>Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February</article-title><source>Euro Surveill</source><person-group><name name-style="western"><surname>Grint</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Wing</surname><given-names>K</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>E</given-names></name><etal/></person-group><volume>26</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2021.26.11.2100256</pub-id><pub-id pub-id-type="pmcid">PMC7976383</pub-id><pub-id pub-id-type="pmid">33739254</pub-id></element-citation></ref><ref id="REF53"><label>53</label><element-citation publication-type="journal"><article-title>Detection of a SARS-CoV-2 variant of concern in South Africa</article-title><source>Nature</source><person-group><name name-style="western"><surname>Tegally</surname><given-names>H</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>E</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M</given-names></name><etal/></person-group><fpage>438</fpage><lpage>443</lpage><volume>592</volume><year>2021</year><pub-id pub-id-type="pmid">33690265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03402-9</pub-id></element-citation></ref><ref id="REF54"><label>54</label><element-citation publication-type="journal"><article-title>Antibody evasion by the P.1 strain of SARS-CoV-2</article-title><source>Cell</source><person-group><name name-style="western"><surname>Dejnirattisai</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Supasa</surname><given-names>P</given-names></name><etal/></person-group><fpage>2939</fpage><lpage>2954</lpage><volume>184</volume><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://10.1016/j.cell.2021.03.055">http://10.1016/j.cell.2021.03.055</uri><pub-id pub-id-type="pmid">33852911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.03.055</pub-id><pub-id pub-id-type="pmcid">PMC8008340</pub-id></element-citation></ref><ref id="REF55"><label>55</label><element-citation publication-type="journal"><article-title>Furin cleavage site is key to SARS-CoV-2 pathogenesis</article-title><source>bioRxiv</source><person-group><name name-style="western"><surname>Johnson</surname><given-names>BA</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Kalveram</surname><given-names>B</given-names></name><etal/></person-group><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1101/2020.08.26.268854">http://dx.doi.org/10.1101/2020.08.26.268854</uri></element-citation></ref><ref id="REF56"><label>56</label><element-citation publication-type="book"><article-title>Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)</article-title><person-group><name name-style="western"><surname>Aleem</surname><given-names>A</given-names></name><name name-style="western"><surname>Akbar Samad</surname><given-names>AB</given-names></name><name name-style="western"><surname>Slenker</surname><given-names>AK</given-names></name></person-group><publisher-loc>Treasure Island, FL</publisher-loc><publisher-name>StatPearls Publishing</publisher-name><year>2022</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34033342/">https://pubmed.ncbi.nlm.nih.gov/34033342/</uri><pub-id pub-id-type="pmid">34033342</pub-id></element-citation></ref><ref id="REF57"><label>57</label><element-citation publication-type="website"><article-title>Report 49 - Growth, population distribution and immune escape of Omicron in England</article-title><date-in-citation content-type="access-date"><month>2</month><year>2022</year></date-in-citation><year>2022</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-49-omicron/">http://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-49-omicron/</uri></element-citation></ref><ref id="REF58"><label>58</label><element-citation publication-type="journal"><article-title>SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Sheikh</surname><given-names>A</given-names></name><name name-style="western"><surname>McMenamin</surname><given-names>J</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>B</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>C</given-names></name></person-group><fpage>2461</fpage><lpage>2462</lpage><volume>397</volume><year>2021</year><pub-id pub-id-type="pmid">34139198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01358-1</pub-id><pub-id pub-id-type="pmcid">PMC8201647</pub-id></element-citation></ref><ref id="REF59"><label>59</label><element-citation publication-type="journal"><article-title>Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name><name name-style="western"><surname>Blackwelder</surname><given-names>W</given-names></name><etal/></person-group><fpage>2173</fpage><lpage>2184</lpage><volume>398</volume><year>2021</year><pub-id pub-id-type="pmid">34774196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02000-6</pub-id><pub-id pub-id-type="pmcid">PMC8584828</pub-id></element-citation></ref><ref id="REF60"><label>60</label><element-citation publication-type="journal"><article-title>Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Lopez Bernal</surname><given-names>J</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C</given-names></name><etal/></person-group><fpage>585</fpage><lpage>594</lpage><volume>385</volume><year>2021</year><pub-id pub-id-type="pmid">34289274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2108891</pub-id><pub-id pub-id-type="pmcid">PMC8314739</pub-id></element-citation></ref><ref id="REF61"><label>61</label><element-citation publication-type="journal"><article-title>Impact of delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK</article-title><source>medRxiv</source><person-group><name name-style="western"><surname>Pouwels</surname><given-names>KB</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>E</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>PC</given-names></name></person-group><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1101/2021.08.18.21262237">https://doi.org/10.1101/2021.08.18.21262237</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01548-7</pub-id><pub-id pub-id-type="pmcid">PMC8674129</pub-id><pub-id pub-id-type="pmid">34650248</pub-id></element-citation></ref><ref id="REF62"><label>62</label><element-citation publication-type="journal"><article-title>Structure-function analyses of new SARS-CoV-2 variants B.1.1.7, B.1.351 and B.1.1.28.1: clinical, diagnostic, therapeutic and public health implications</article-title><source>Viruses</source><person-group><name name-style="western"><surname>Singh</surname><given-names>J</given-names></name><name name-style="western"><surname>Samal</surname><given-names>J</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name><etal/></person-group><fpage>1866</fpage><lpage>1868</lpage><volume>13</volume><year>2021</year><pub-id pub-id-type="pmid">33803400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13030439</pub-id><pub-id pub-id-type="pmcid">PMC8000172</pub-id></element-citation></ref><ref id="REF63"><label>63</label><element-citation publication-type="journal"><article-title>Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants</article-title><source>Res Sq</source><person-group><name name-style="western"><surname>Ikegame</surname><given-names>S</given-names></name><name name-style="western"><surname>Siddiquey</surname><given-names>MN</given-names></name><name name-style="western"><surname>Hung</surname><given-names>CT</given-names></name><etal/></person-group><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.21203/rs.3.rs-400230/v1">http://dx.doi.org/10.21203/rs.3.rs-400230/v1</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-24909-9</pub-id><pub-id pub-id-type="pmcid">PMC8313705</pub-id><pub-id pub-id-type="pmid">34312390</pub-id></element-citation></ref><ref id="REF64"><label>64</label><element-citation publication-type="journal"><article-title>ChAdOx1 nCoV-19 vaccine efficacy against the B.1.351 variant. Reply</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Izu</surname><given-names>A</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name></person-group><fpage>571</fpage><lpage>572</lpage><volume>385</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2110093</pub-id><pub-id pub-id-type="pmid">34289271</pub-id></element-citation></ref><ref id="REF65"><label>65</label><element-citation publication-type="journal"><article-title>How effective are Covishield and Covaxin against Delta Plus? Report in 7-10 days</article-title><date-in-citation content-type="access-date"><month>10</month><year>2021</year></date-in-citation><fpage>7</fpage><lpage>10</lpage><volume>in</volume><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hindustantimes.com/india-news/how-effective-are-covishield-and-covaxin-against-delta-plus-report-in-7-10-days-101624626339807.html">https://www.hindustantimes.com/india-news/how-effective-are-covishield-and-covaxin-against-delta-plus-report-in-7-10-days-101624626339807.html</uri></element-citation></ref><ref id="REF66"><label>66</label><element-citation publication-type="journal"><article-title>Coronavirus disease (COVID-19): vaccines</article-title><date-in-citation content-type="access-date"><month>3</month><year>2022</year></date-in-citation><volume>https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines</volume><year>2022</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines">https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines</uri></element-citation></ref><ref id="REF67"><label>67</label><element-citation publication-type="journal"><article-title>Effectiveness of BNT162b2 vaccine against omicron variant in South Africa</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Collie</surname><given-names>S</given-names></name><name name-style="western"><surname>Champion</surname><given-names>J</given-names></name><name name-style="western"><surname>Moultrie</surname><given-names>H</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>LG</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name></person-group><fpage>494</fpage><lpage>496</lpage><volume>386</volume><year>2022</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1056/NEJMc2119270">http://dx.doi.org/10.1056/NEJMc2119270</uri><pub-id pub-id-type="pmid">34965358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2119270</pub-id><pub-id pub-id-type="pmcid">PMC8757569</pub-id></element-citation></ref><ref id="REF68"><label>68</label><element-citation publication-type="website"><article-title>SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 18</article-title><date-in-citation content-type="access-date"><month>10</month><year>2021</year></date-in-citation><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf</uri></element-citation></ref><ref id="REF69"><label>69</label><element-citation publication-type="journal"><article-title>Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines</article-title><source>J Med Virol</source><person-group><name name-style="western"><surname>Araf</surname><given-names>Y</given-names></name><name name-style="western"><surname>Akter</surname><given-names>F</given-names></name><name name-style="western"><surname>Tang</surname><given-names>YD</given-names></name><name name-style="western"><surname>Fatemi</surname><given-names>R</given-names></name><name name-style="western"><surname>Parvez</surname><given-names>MS</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>MG</given-names></name></person-group><fpage>1825</fpage><lpage>1832</lpage><volume>94</volume><year>2022</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.1002/jmv.27588">http://dx.doi.org/10.1002/jmv.27588</uri><pub-id pub-id-type="pmid">35023191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.27588</pub-id><pub-id pub-id-type="pmcid">PMC9015557</pub-id></element-citation></ref><ref id="REF70"><label>70</label><element-citation publication-type="journal"><article-title>Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Walter</surname><given-names>EB</given-names></name><name name-style="western"><surname>Talaat</surname><given-names>KR</given-names></name><name name-style="western"><surname>Sabharwal</surname><given-names>C</given-names></name><etal/></person-group><fpage>35</fpage><lpage>46</lpage><volume>386</volume><year>2022</year><pub-id pub-id-type="pmid">34752019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2116298</pub-id><pub-id pub-id-type="pmcid">PMC8609605</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>